Table 4. Treatment effects on serum lipids.^1-4.

	Con	E+P	E+P+T	ANOVA P value
TC (mg/dl)
Baseline (0 wk)	253.0 ± 20.6	274.3 ± 19.3	223.3 ± 17.3	0.16
High-dose T (8 wk)	227.1 ± 11.2	175.3 ± 10.9b	215.1 ± 9.8c	0.009
Low-dose T (16 wk)	171.0 ± 11.9	153.7 ± 11.6	153.2 ± 10.4	0.47
LDL+VLDL (mg/dl)
Baseline (0 wk)	150.9 ± 24.0	188.9 ± 22.5	119.8 ± 20.1	0.10
High-dose T (8 wk)	125.0 ± 8.2	92.9 ± 8.1a	128.4 ± 7.2c	0.01
Low-dose T (16 wk)	170.3 ± 6.8	186.0 ± 6.8	184.8 ± 6.0	0.20
HDL (mg/dl)
Baseline (0 wk)	102.1 ± 8.6	85.4 ± 8.0	103.5 ± 7.2	0.22
High-dose T (8 wk)	100.9 ± 6.7	88.7 ± 6.5	82.5 ± 5.6	0.13
Low-dose T (16 wk)	79.8 ± 5.9	59.6 ± 5.8	63.4 ± 5.0	0.052
Triglycerides (mg/dl)
Baseline (0 wk)	53.1 ± 8.9	39.6 ± 8.3	37.7 ± 7.4	0.39
High-dose T (8 wk)	24.4 ± 11.2	51.9 ± 7.0a	62.2 ± 6.3b	0.004
Low-dose T (16 wk)	44.0 ± 8.6	37.9 ± 7.9	51.2 ± 7.1	0.46
TC:HDL
Baseline (0 wk)	2.64 ± 0.47	3.56 ± 0.44	2.27 ± 0.39	0.11
High-dose T (8 wk)	2.31 ± 0.21	2.15 ± 0.21	2.74 ± 0.18	0.12
Low-dose T (16 wk)	2.25 ± 0.35	2.74 ± 0.35	2.93 ± 0.30	0.34

¹Con = Control (placebo); E = oral 17β-Estradiol; P = oral micronized progesterone; T = testosterone administered via subcutaneous pellets; TC, total cholesterol; LDL, low density lipoprotein; VLDL, very low density lipoprotein; HDL, high density lipoprotein. n = 7, 8, and 10 for Con, E+P, and E+P+T groups, respectively, for all measures.

²Values represent mean ± standard error.

³For conversion to SI units (mmol/l), divide by 38.67 for total cholesterol, LDL+VLDL, and HDL, and by 88.57 for triglycerides.

⁴Letters indicate significant differences with control group (^a P < 0.05, ^b P < 0.01) or with E+P group (^cP < 0.05).